Brief: Ocugen Gains FDA Alignment on Key Aspects of OCU400—Modifier Gene Therapy—Pivotal Phase 3 Study Design

Ocugen

21/12/2023 12:20

Dec 21 (Reuters) - Ocugen Inc  OCGN.O :
    * OCUGEN GAINS FDA ALIGNMENT ON KEY ASPECTS OF
OCU400—MODIFIER
GENE THERAPY—PIVOTAL PHASE 3 STUDY DESIGN
    * OCUGEN: PHASE 3 CLINICAL TRIAL WILL ENROLL BROADER GROUP
OF RP
PATIENTS, INCLUDING PATIENTS WITH MOST COMMON RHO GENE MUTATION

Source text for Eikon:  ID:nGNX7jpddv 
Further company coverage:  OCGN.O 

 ((Reuters.Briefs@thomsonreuters.com;))